Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?
Executive Summary
Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.
You may also be interested in...
Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
Sanofi's Q3 sales grow by 10% and net income by 4.1% as Genzyme acquisition compensates for increasing generic competition to leading products.
Sanofi's Deal With Medco/UBC Seeks Payer Perspective To Inform Drug R&D, Marketing
The multi-year, global data, research and consulting agreement will focus primarily on drugs in Phase II or III.
Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need
A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into Sanofi's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme, Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy.